Why Lakefront Biotherapeutics NV’s (LKFT) Stock Is Up 5.40%
As of Thursday, November 12, Lakefront Biotherapeutics NV’s LKFT share price has surged by 5.40%, which has investors questioning if this is right time to sell.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Michael Rose
Michael Rose
Rosalio Madrigal
Rosalio Madrigal
| Share Statistics | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,136.8 | $203.5 | 57% |
|
| Shares Out (Mil) | 75.4 | 55.2 | 56% |
|
| Institutional Ownership | 100.0% | 93.3% | 99% |
|
| Float (Mil) | 22.5 | 40.4 | 30% |
|
| Beta | 0.01 | 1.05 | 6% |
|
| Avg Daily Volume (000s) | 271 | 569 | 49% |
|
| Price Change (52-week) |
9.3% | 38.8% | 63% |
|
| Growth | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.4% | 13.6% | 77% |
|
| Net Income (5yr) | 24.6% | (10.7%) | 80% |
|
| EPS (5yr) | 24.5% | 15.4% | 75 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (39.2%) | (15.7%) | 12% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.216) | ($0.016) | ($1.522) | |
| Month Ago EPS | ($0.181) | ($0.780) | ($1.164) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.181) | ($0.780) | ($1.164) | |
| Year/Year Chg | (735.3%) | (100.3%) | (135.6%) | |
| Financials | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,132 | $40 | 51% |
|
| Net Income (TTM) (Mil) | $682 | ($44) | 81% |
|
| EPS (TTM) | $10.345 | ($1.400) | 94% |
|
| Operating Cash Flow (TTM) (Mil) | ($259) | ($35) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $40 | $-0 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | ($293) | $142 | 0% |
|
| Valuation | LKFT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.59 | 1.96 | 15% |
|
| P/E | 3.2 | 16.9 | 3% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 0.9 | 6% |
|
| Ratios | LKFT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 67.6% | 67.6% | 79% |
|
| Net Margin | 60.2% | (50.8%) | 98% |
|
| ROA | 16.7% | (47.0%) | 94% |
|
| ROE | 20.4% | (51.8%) | 80% |
|
| Liabilities to Assets | 2.6% | 29.6% | 1% |
|
| F-Score | 3 | 3 | na |
|
Lakefront Biotherapeutics NV did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors